Press Releases

03.01.2017

Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency

02.28.2017

Pfizer Prices €4,000,000,000 Debt Offering

02.28.2017

Pfizer Commits $4M to North Carolina Biotechnology Center Gene Therapy Fellowship Program

02.28.2017

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

02.28.2017

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review

02.27.2017

Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO

02.24.2017

Pfizer Prices $1,065,000,000 Debt Offering

02.23.2017

Ronald E. Blaylock Elected to Pfizer’s Board of Directors

02.22.2017

Startup accelerator BaseLaunch aims to attract promising healthcare ventures to Basel, Europe’s leading life sciences hub.

02.21.2017

Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

02.17.2017

New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a

02.16.2017

Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)